Abstract | OBJECTIVES: METHODS: RESULTS: CONCLUSIONS:
Lycopene, as prescribed in our study, did not appear effective for androgen-independent prostate cancer. The patients' reasons for enrolling in this trial were positive and realistic.
|
Authors | Aminah Jatoi, Patrick Burch, David Hillman, Joanne M Vanyo, Shaker Dakhil, Daniel Nikcevich, Kendrith Rowland, Roscoe Morton, Patrick J Flynn, Charles Young, Winston Tan, North Central Cancer Treatment Group |
Journal | Urology
(Urology)
Vol. 69
Issue 2
Pg. 289-94
(Feb 2007)
ISSN: 1527-9995 [Electronic] United States |
PMID | 17320666
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Androgens
- Anticarcinogenic Agents
- Carotenoids
- Prostate-Specific Antigen
- Lycopene
|
Topics |
- Administration, Oral
- Aged
- Aged, 80 and over
- Androgens
(metabolism)
- Anticarcinogenic Agents
(therapeutic use)
- Biopsy, Needle
- Carotenoids
(therapeutic use)
- Complementary Therapies
- Dietary Supplements
- Follow-Up Studies
- Humans
- Lycopene
- Solanum lycopersicum
- Male
- Middle Aged
- Neoplasm Staging
- Neoplasms, Hormone-Dependent
(pathology, therapy)
- Patient Selection
- Probability
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(pathology, therapy)
- Risk Assessment
- Treatment Outcome
|